Crossmark

Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance

Crossref DOI link: https://doi.org/10.1007/s11095-023-03548-3

Published Online: 2023-06-22

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Yihua Bruce http://orcid.org/0000-0001-8043-6530
Briggs, Katharine T.

Taraban, Marc B.
Funding

Funding for this research was provided by:

U.S. Food and Drug Administration (75F40119C10104)

National Institute for Innovation in Manufacturing Biopharmaceuticals (ARP-25)
License Information

Text and Data Mining valid from 2023-06-22

Version of Record valid from 2023-06-22
More Information

Article History

Received: 3 May 2023

Accepted: 3 June 2023

First Online: 22 June 2023

Change Date: 10 August 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11095-023-03575-0

Updates are available Correction dated 2023-08-10

Click to view Correction: https://doi.org/10.1007/s11095-023-03575-0